Aptinyx Inc (NASDAQ:APTX) has been assigned a consensus rating of “Buy” from the nine analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among brokers that have covered the stock in the last year is $13.50.
Several research analysts have weighed in on the company. JPMorgan Chase & Co. cut Aptinyx from a “neutral” rating to an “underweight” rating in a research report on Tuesday, August 13th. ValuEngine raised Aptinyx from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Cowen reaffirmed a “buy” rating on shares of Aptinyx in a report on Thursday, November 14th. Zacks Investment Research upgraded shares of Aptinyx from a “sell” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Wedbush started coverage on shares of Aptinyx in a research report on Thursday, September 12th. They issued an “outperform” rating and a $7.00 price target on the stock.
Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Aptinyx by 56.6% in the 2nd quarter. Vanguard Group Inc. now owns 728,689 shares of the company’s stock worth $2,434,000 after purchasing an additional 263,458 shares during the period. Marshall Wace LLP increased its position in shares of Aptinyx by 21.9% during the second quarter. Marshall Wace LLP now owns 306,320 shares of the company’s stock valued at $1,023,000 after buying an additional 54,967 shares during the period. Citadel Advisors LLC lifted its holdings in shares of Aptinyx by 91.4% in the second quarter. Citadel Advisors LLC now owns 100,680 shares of the company’s stock worth $336,000 after buying an additional 48,074 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Aptinyx in the third quarter worth about $260,000. Finally, Jane Street Group LLC purchased a new stake in shares of Aptinyx in the second quarter worth about $222,000. Institutional investors own 52.14% of the company’s stock.
Shares of Aptinyx stock traded down $0.05 during mid-day trading on Friday, hitting $3.15. 118,152 shares of the stock were exchanged, compared to its average volume of 270,167. Aptinyx has a 12 month low of $2.61 and a 12 month high of $26.74. The company has a 50-day simple moving average of $3.22 and a 200 day simple moving average of $3.43. The company has a market capitalization of $111.76 million, a P/E ratio of -1.20 and a beta of 0.01.
Aptinyx (NASDAQ:APTX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.44) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.44). The company had revenue of $0.94 million during the quarter, compared to the consensus estimate of $0.91 million. Aptinyx had a negative return on equity of 44.24% and a negative net margin of 1,523.09%. On average, research analysts predict that Aptinyx will post -1.92 EPS for the current fiscal year.
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Featured Article: Support Level
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.